The collaboration will test whether LNP-mRNA formulations can be stabilized by spray-drying them with AmorphOX while preserving the nanoparticles’ critical properties and the functional activity of the mRNA. Lipid nanoparticles protect the mRNA and carry it into cells, but keeping both the mRNA and its lipid carrier stable makes vaccines harder to store and distribute. A powder format could make handling, transport and storage more flexible.

The project combines Orexo’s expertise in powder formulation and intranasal drug delivery with SVF Vaccines’ expertise in vaccine development. Positive results could support further development toward needle-free intranasal vaccines, although that would require further evaluation of the powder’s properties, tolerability and mucosal immune response. The results of the initial study will guide decisions on further development and a possible expansion of the collaboration.

“This collaboration will explore whether AmorphOX can address an important formulation challenge in mRNA vaccine development,” said Nikolaj Sørensen, President and CEO of Orexo.